Anti-Heparan Sulfate Proteoglycan 2/Perlecan antibody [A7L6] - BSA free (ab212460)

Overview

  • Product name

    Anti-Heparan Sulfate Proteoglycan 2/Perlecan antibody [A7L6] - BSA free
    See all Heparan Sulfate Proteoglycan 2/Perlecan primary antibodies
  • Description

    Rat monoclonal [A7L6] to Heparan Sulfate Proteoglycan 2/Perlecan - BSA free
  • Host species

    Rat
  • Specificity

    ab212460 does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan.
  • Tested applications

    Suitable for: Flow Cyt, IHC-P, ICC/IFmore details
  • Species reactivity

    Reacts with: Mouse, Cow, Human, Pig, Fish, Monkey
  • Immunogen

    Tissue, cells or virus corresponding to Mouse Heparan Sulfate Proteoglycan 2/Perlecan. Murine EHS laminin preparation.
    Database link: Q05793

  • Positive control

    • Breast carcinomas, squamous cell carcinomas.
  • General notes

     This product was previously labelled as Heparan Sulfate Proteoglycan 2

     

Properties

Applications

Our Abpromise guarantee covers the use of ab212460 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use 0.5-1µg for 106 cells.

in 0.1 ml

IHC-P Use a concentration of 1 - 2 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ICC/IF Use a concentration of 0.5 - 1 µg/ml.

Target

  • Function

    Integral component of basement membranes. Component of the glomerular basement membrane (GBM), responsible for the fixed negative electrostatic membrane charge, and which provides a barrier which is both size- and charge-selective. It serves as an attachment substrate for cells. Plays essential roles in vascularization. Critical for normal heart development and for regulating the vascular response to injury. Also required for avascular cartilage development.
    Endorepellin in an anti-angiogenic and anti-tumor peptide that inhibits endothelial cell migration, collagen-induced endothelial tube morphogenesis and blood vessel growth in the chorioallantoic membrane. Blocks endothelial cell adhesion to fibronectin and type I collagen. Anti-tumor agent in neovascularization. Interaction with its ligand, integrin alpha2/beta1, is required for the anti-angiogenic properties. Evokes a reduction in phosphorylation of receptor tyrosine kinases via alpha2/beta1 integrin-mediated activation of the tyrosine phosphatase, PTPN6.
    The LG3 peptide has anti-angiogenic properties that require binding of calcium ions for full activity.
  • Tissue specificity

    Found in the basement membranes.
  • Involvement in disease

    Defects in HSPG2 are the cause of Schwartz-Jampel syndrome (SJS1) [MIM:255800]; a rare autosomal recessive disorder characterized by permanent myotonia (prolonged failure of muscle relaxation) and skeletal dysplasia, resulting in reduced stature, kyphoscoliosis, bowing of the diaphyses and irregular epiphyses.
    Defects in HSPG2 are the cause of dyssegmental dysplasia Silverman-Handmaker type (DDSH) [MIM:224410]. The dyssegmental dysplasias are rare, autosomal recessive skeletal dysplasias with anisospondyly and micromelia. There are two recognized types: the severe, lethal DDSH and the milder Rolland-Desbuquois form. Individuals with DDSH also have a flat face, micrognathia, cleft palate and reduced joint mobility, and frequently have an encephalocoele. The endochondral growth plate is short, the calcospherites (which are spherical calcium-phosphorus crystals produced by hypertrophic chondrocytes) are unfused, and there is mucoid degeneration of the resting cartilage.
  • Sequence similarities

    Contains 4 EGF-like domains.
    Contains 22 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 11 laminin EGF-like domains.
    Contains 3 laminin G-like domains.
    Contains 3 laminin IV type A domains.
    Contains 4 LDL-receptor class A domains.
    Contains 1 SEA domain.
  • Post-translational
    modifications

    Proteolytic processing produces the C-terminal angiogenic peptide, endorepellin. This peptide can be further processed to produce the LG3 peptide.
    N- and O-glycosylated; contains three heparan sulfate chains. The LG3 peptide contains at least three and up to five potential O-glycosylation sites but no N-glycosylation.
  • Cellular localization

    Secreted > extracellular space > extracellular matrix > basement membrane.
  • Information by UniProt
  • Database links

  • Alternative names

    • Basement membrane specific heparan sulfate proteoglycan core protein antibody
    • Endorepellin (domain V region) antibody
    • Heparan sulfate proteoglycan of basement membrane antibody
    • HSPG 2 antibody
    • HSPG antibody
    • Hspg2 antibody
    • LG3 peptide antibody
    • Perlecan antibody
    • PGBM_HUMAN antibody
    • PLC antibody
    • Schwartz Jampel syndrome 1 (chondrodystrophic myotonia) antibody
    • SJA antibody
    • SJS antibody
    • SJS1 antibody
    see all

References

ab212460 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab212460.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up